NASDAQ:CORT - Corcept Therapeutics Stock Price, News, Headlines & Rumors

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

Corcept Therapeutics Incorporated (NASDAQ:CORT) issued its quarterly earnings results on Thursday, August, 9th. The biotechnology company reported $0.20 EPS for the quarter, missing the consensus estimate of $0.24 by $0.04. The biotechnology company had revenue of $62.31 million for the quarter, compared to analyst estimates of $68.49 million. Corcept Therapeutics had a return on equity of 38.53% and a net margin of 68.32%. The firm's quarterly revenue was up 75.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.13 EPS. View Corcept Therapeutics' Earnings History.

Corcept Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for Corcept Therapeutics.

4 Wall Street analysts have issued 1 year target prices for Corcept Therapeutics' shares. Their predictions range from $11.00 to $32.00. On average, they expect Corcept Therapeutics' stock price to reach $23.75 in the next twelve months. This suggests a possible upside of 90.5% from the stock's current price. View Analyst Price Targets for Corcept Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corcept Therapeutics.

Corcept Therapeutics saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 18,122,510 shares, an increase of 8.0% from the July 13th total of 16,779,082 shares. Based on an average daily volume of 1,226,071 shares, the days-to-cover ratio is currently 14.8 days. Currently, 17.7% of the shares of the company are sold short. View Corcept Therapeutics' Current Options Chain.

Some companies that are related to Corcept Therapeutics include GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), Ligand Pharmaceuticals (LGND), FibroGen (FGEN), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC- (GWPH), Madrigal Pharmaceuticals (MDGL), Endo International (ENDP) and Horizon Pharma (HZNP).

News headlines about CORT stock have trended somewhat positive on Tuesday, according to Accern. The research group rates the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Corcept Therapeutics earned a media and rumor sentiment score of 0.17 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 48.17 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term. View Recent Headlines for Corcept Therapeutics.

Corcept Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.32%), Federated Investors Inc. PA (10.34%), Ingalls & Snyder LLC (6.35%), Renaissance Technologies LLC (3.77%), Acadian Asset Management LLC (2.42%) and Dimensional Fund Advisors LP (1.44%). Company insiders that own Corcept Therapeutics stock include David L Mahoney, G Leonard Baker Jr, Gary Charles Robb, James N Wilson, Joseph K Belanoff, Patrick G Enright, Renee D Gala and Robert S Fishman. View Institutional Ownership Trends for Corcept Therapeutics.

CORT stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Acadian Asset Management LLC, Renaissance Technologies LLC, Russell Investments Group Ltd., American Century Companies Inc., Globeflex Capital L P, GSA Capital Partners LLP and Smith Asset Management Group LP. Company insiders that have sold Corcept Therapeutics company stock in the last year include G Leonard Baker Jr and Robert S Fishman. View Insider Buying and Selling for Corcept Therapeutics.

CORT stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Ingalls & Snyder LLC, Fuller & Thaler Asset Management Inc., KBC Group NV, AJ Wealth Strategies LLC, HL Financial Services LLC, Wells Fargo & Company MN and Oak Ridge Investments LLC. Company insiders that have bought Corcept Therapeutics stock in the last two years include Gary Charles Robb and Renee D Gala. View Insider Buying and Selling for Corcept Therapeutics.

Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CORT stock can currently be purchased for approximately $12.47.

Corcept Therapeutics has a market capitalization of $1.54 billion and generates $159.20 million in revenue each year. The biotechnology company earns $129.12 million in net income (profit) each year or $0.44 on an earnings per share basis. Corcept Therapeutics employs 136 workers across the globe.

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-327-3270 or via email at [email protected]